Lilly To Release Early-Stage Pipeline Data Targeting Key Cancer Pathwa
- This topic has 8 replies, 4 voices, and was last updated 10 years, 3 months ago by
.
-
Posts
-
Abstract # 2339: Prevalence of MET expression, activating mutations of KRAS and IDH1/2, and ROS1 fusions in cholangiocarcinoma patient tumor samples.
Kris…you have the right to ask for the results if indeed the data has been released. However; compiling the data is a lengthy process. In fact, often times we see the end results of a clinical trial, but have to await further study evaluations.
It appears that this clinical trial is still undergoing evaluation and the above mentioned poster refers to the in vitro tumor studies confirming the data compiled (so far) from the clinical study in process.
We just have to be patient, but who likes that?Hugs,
MarionI am a little bit confused. “Early stage pipeline data” sounds like Lily was going to release some data from their phase 1/2 trial. However, “preclinical evaluation” seems more like mouse model type results.
Here is the AACR abstract:
Looks like cell lines and mouse models. Still good stuff, but I was hoping for some good news data from their trials.
Jason
This is the clinical trial:
http://clinicaltrials.gov/show/NCT01285037Lilly To Release Early-Stage Pipeline Data Targeting Key Cancer Pathways At AACR 2014.
c-MET Inhibitor (LY2801653)
Abstract #4403: Poster Presentation: Tuesday April 8, 2014 1:00 pm to 5:00 pm
Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models
Author/Speaker: S. Betty Yan, Ph.D.
Location: Hall A-E, Section 24http://www.ncbi.nlm.nih.gov/pubmed/23275061
- The forum ‘New Developments’ is closed to new topics and replies.